COVID-19 Central Research Database

582 items found

Blog Posts (110)

  • Teenager Develops Possible Treatment ... Awarded $25,000!!!

    A teenage girl in Texas is getting national recognition for her work on a potential treatment for COVID-19 ... and she's already getting paid. Anika Chebrolu, a 14-year-old freshman at Independence High School in Frisco, is being hailed as the country's top young scientist ... and she won $25,000 for her potential coronavirus breakthrough. Anika won the 3M Young Scientist Challenge for her hard work identifying a potential drug to treat COVID-19. The brilliant student says she developed -- while in the 8th grade -- a molecule that binds to a protein on the SARS-CoV-2 virus, and essentially stops the virus from functioning. A brilliant discovery for an adult, much less a kid. This part will blow your mind, unless you're a scientist -- Anika says she started with a database of over 682 million compounds and used a few computer programs to figure out how and where the molecule would bind to the virus. We'll take her word for it. Anika was still in middle school when she entered the contest and was initially planning her science project around finding ways to combat seasonal flu. But, like many pro scientists, she pivoted when the pandemic hit. She says she drew inspiration from stories about people suffering from COVID-19 ... and she's also crediting her grandpa, a chemistry professor, for steering her toward science. Ref Credit and Sourc of Information

  • Diagnosis process of Covid-19 : How to Obtain a Nasopharyngeal Swab Specimen

    Collection of specimens from the surface of the respiratory mucosa with nasopharyngeal swabs is a procedure used for the diagnosis of Covid-19 in adults and children.1-4 The procedure is also commonly used to evaluate patients with suspected respiratory infection caused by other viruses and some bacteria. This video describes the collection of nasopharyngeal specimens for detection of Covid-19, the illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are no specific contraindications for collecting specimens with nasopharyngeal swabs. However, clinicians should be cautious if the patient has had recent nasal trauma or surgery, has a markedly deviated nasal septum, or has a history of chronically blocked nasal passages or severe coagulopathy. Preparation and Equipment Nasopharyngeal swabs are specifically manufactured to have long, flexible shafts made of plastic or metal and tips made of polyester, rayon, or flocked nylon. In addition to nasopharyngeal swabs, you will need personal protective equipment (PPE), including a gown, nonsterile gloves, a protective mask, and a face shield, as described below. Make sure that all sample tubes have been labeled and that the appropriate requisition forms have been filled out before starting the procedure. Figure 1. Personal Protective Equipment.It is essential that you follow the pertinent respiratory and contact precautions specified by the Centers for Disease Control and Prevention (CDC) and by your own institution and that you put on the PPE correctly (Figure 1). If possible, you should put on and take off the PPE in the presence of an observer to make sure there are no breaks in technique that may pose a risk of contamination. First, put on a protective gown, wash your hands with soap and water (or use an alcohol-based solution), and put on a pair of nonsterile gloves. Then put on a protective mask with a rating of N95 or higher, as recommended by the CDC. Finally, put on a face shield for face and eye protection. Procedure Figure 2. Patient Wearing a Mask.Figure 3. Obtaining the Nasopharyngeal Swab Specimen.Masks are recommended for all patients suspected of having Covid-19 (Figure 2). Ask the patient to take off her mask and blow her nose into a tissue to clear excess secretions from the nasal passages. Remove the swab from the packaging. Tilt the patient’s head back slightly, so that the nasal passages become more accessible. Ask the patient to close her eyes to lessen the mild discomfort of the procedure. Gently insert the swab along the nasal septum, just above the floor of the nasal passage, to the nasopharynx, until resistance is felt (Figure 3). Insert the swab into the nostril, parallel to the palate. If you detect resistance to the passage of the swab, back off and try reinserting it at a different angle, closer to the floor of the nasal canal. The swab should reach a depth equal to the distance from the nostrils to the outer opening of the ear. The CDC recommends leaving the swab in place for several seconds to absorb secretions and then slowly removing the swab while rotating it. Your institution may also recommend rotating the swab in place several times before removing it. Ask the patient to reapply her mask. Handling of the Specimen Figure 4. Handling the Nasopharyngeal Swab Specimen.Open the collection tube and insert the swab into the tube. Break the swab at the groove and discard what remains of the swab. Close the labeled collection tube, wipe the tube with a surface-disinfectant wipe, and insert the tube into an open biohazard bag held by an assistant (Figure 4). Depending on institutional practices, you may instead return the sample to its original packaging for transport. Follow the CDC directions for direct processing of the swab specimen or placement of the swab in media with or without refrigeration. Removing Personal Protective Equipment Remove your PPE as shown in the video and described here or in accordance with the standards at your institution. First, remove your gown and gloves. Clean your hands with an alcohol-based solution or soap and water. Put on a new pair of gloves, and then remove your face shield and either dispose of it or clean and store it in accordance with the guidelines at your institution. Remove your gloves, rewash your hands, and put on another pair of gloves; then remove your mask and follow your institutional guidelines for disposal or reuse. Finally, remove the last pair of gloves and wash your hands. Summary This video demonstrates the collection of specimens from the surface of the respiratory mucosa with nasopharyngeal swabs for the diagnosis of Covid-19 in adults and in children. It is important to use approved PPE and the appropriate technique to minimize the possibility of spreading the virus. Ref Credit and Source of Information

  • SARS-CoV-2 surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change

    Mycroft-West et al. (2020)Running title: SARS-CoV-2 surface S1 Receptor Binding Domain binds heparinThe 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding Many pathogens take advantage of the dependence of the host on the interaction of hundreds of extracellular proteins w/the glycosaminoglycans heparan sulphate to regulate homeostasis and use heparan sulphate as a means to adhere & gain access to cells. Moreover, mucosal epithelia such as that of the respiratory tract are protected by a layer of mucin polysaccharides, which are usually sulphated. The polydisperse, natural products of heparan sulphate and the allied polysaccharide,heparin have been found to be involved & prevent infection by a range of viruses including S-associated coronavirus strain HSR1.Here we use surface plasmon resonance & circular dichroism to measure the interaction between the SARS-CoV- 2 Spike S1 protein RBD (#SARS_CoV_2_S1_RBD)& #heparin. The data demonstrate an interaction between the recombinant surface receptor binding domain & polysaccharide. This has implications for the rapid development of a first-line therapeutic by repurposing heparin and for next-generation,tailor-made,GAG-based antivirals. Ref Source of Information

View All

Pages (9)

  • Discussion Forum | Corona ResearchGate

    To see this working, head to your live site. All Posts My Posts Login / Sign up Business Forum Explore the forum below to find answers to all of you business related questions and concerns. Sort by: Recent Activity Create New Post Vivian Creative Antiviral Drug Discovery for SARS-CoV-2 A novel coronavirus (SARS-CoV-2) originally detected in Wuhan, China, has caused an outbreak of viral pneumonia spreading to all provinces of China and lots of countries. Unprecedented efforts and dedication have been devoted to developing effective antiviral drugs to defeat this deadly infectious d Views 0 comments 0 0 Recent Activity: May 05 Dinakaran Pannerselvam Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection Serum samples obtained from unvaccinated persons after infection with the B.1.1.7 (alpha), B.1.351 (beta), or B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the B.1.1.529 (omicron) variant only occasionally. 1 Similarly, level Views 0 comments 0 0 Recent Activity: Mar 24 Vivian Creative SARS-CoV-2 (COVID-19) Related Detection Kits Creative Biolabs is an industry leading supplier of recombinant proteins, antibodies, and kits. In response to the global epidemic of COVID-19, Creative Biolabs has quickly integrated its strengths to offer related proteins, antibodies, and kit products, and provide various SARS-CoV-2 (COVID-19) re Views 0 comments 0 0 Recent Activity: Mar 15 Dinakaran Pannerselvam Neocov - Close relatives of MERS-CoV in bats use ACE2 as their functional receptor | New Variant Middle East Respiratory Syndrome coronavirus (MERS-CoV) and several bat coronaviruses employ Dipeptidyl peptidase-4 (DPP4) as their functional receptors 1 – 4 . However, the receptor for NeoCoV, the closest MERS-CoV relative yet discovered in bats, remains enigmatic 5 . In this study, we unexpectedl Views 0 comments 0 0 Recent Activity: Jan 29 Dinakaran Pannerselvam Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection In addition to the severe impact of acute respiratory disease during the SARS-CoV-2 pandemic, the issue of “Long COVID” illness has impacted large numbers of patients following the initial infection. Wide ranges of Long Covid incidence have been reported, ranging from 30 to 87%. Long COVID has a var Views 0 comments 0 0 Recent Activity: Jan 26 Dinakaran Pannerselvam Omicron blindspots: why it’s hard to track coronavirus variants Researchers are racing to detect Omicron, the latest SARS-CoV-2 variant of concern, by sequencing the genomes of coronaviruses infecting people. But surveillance through genomic sequencing can be slow and patchy, complicating the picture of how and where Omicron spreads. One positive development is Views 1 comment 1 1 Recent Activity: Jan 17 Dinakaran Pannerselvam Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic The emergence of the alpha, beta, and delta SARS-CoV-2 VoCs were associated with new waves of infections, sometimes across the entire world. For example, the increased transmissibility of the delta VoC was associated with, among others, a higher viral load, longer duration of infectiousness, and hig Views 0 comments 0 0 Recent Activity: Dec 06, 2021 Dinakaran Pannerselvam Identification of Human Single-Domain Antibodies against SARS-CoV-2 The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic t Views 1 comment 1 0 Recent Activity: Nov 04, 2021 Dinakaran Pannerselvam SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. He Views 0 comments 0 0 Recent Activity: Jun 08, 2021 Dinakaran Pannerselvam Dexamethasone in Hospitalized Patients with Covid-19 BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS In this controlled, open-label trial comparing a range of possible treatments Views 0 comments 0 0 Recent Activity: May 07, 2021 Dinakaran Pannerselvam COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography COVID-19 is a multiorgan systemic inflammatory disease caused by SARS-CoV-2 virus. Patients with COVID-19 often exhibit cardiac dysfunction and myocardial injury, but imaging evidence is lacking. In the study we detected and evaluated the severity of myocardial dysfunction in COVID-19 patient popula Views 0 comments 0 0 Recent Activity: Apr 29, 2021 Dinakaran Pannerselvam A guideline to limit indoor airborne transmission of COVID-19 The current revival of the American economy is being predicated on social distancing, specifically the Six-Foot Rule, a guideline that offers little protection from pathogen-bearing aerosol droplets sufficiently small to be continuously mixed through an indoor space. The importance of airborne trans Views 0 comments 0 0 Recent Activity: Apr 27, 2021 Dinakaran Pannerselvam SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity The coronaviral spike is the dominant viral antigen and the target of neutralizing antibodies. We show that SARS-CoV-2 spike binds biliverdin and bilirubin, the tetrapyrrole products of haem metabolism, with nanomolar affinity. Using cryo-electron microscopy and X-ray crystallography, we mapped the Views 0 comments 0 0 Recent Activity: Apr 26, 2021 Dinakaran Pannerselvam The impact of viral mutations on recognition by SARS-CoV-2 specific T-cells We identify amino acid variants within dominant SARS-CoV-2 T-cell epitopes by interrogating global sequence data. Several variants within nucleocapsid and ORF3a epitopes have arisen independently in multiple lineages and result in loss of recognition by epitope-specific T-cells assessed by IFN-γ and Views 0 comments 0 0 Recent Activity: Apr 23, 2021 Dinakaran Pannerselvam Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibod Views 0 comments 0 0 Recent Activity: Apr 16, 2021 Dinakaran Pannerselvam Intersecting pandemics of tuberculosis & COVID-19: population-level & patient-level impact, clinical presentation, & correctiveinterventions The aim of this Series paper is to review the interactions between COVID-19 and tuberculosis, including the population-level impact of COVID-19 on tuberculosis outcomes, the clinical presentation and diagnosis of tuberculosis–COVID-19 co-infection, the patient-level impact of COVID-19 on the managem Views 0 comments 0 0 Recent Activity: Mar 24 Dinakaran Pannerselvam SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study Background The memory immune response is crucial for preventing reinfection or reducing disease severity. However, the robustness and functionality of the humoral and T-cell response to SARS-CoV-2 remains unknown 12 months after initial infection. The aim of this study is to investigate the durabili Views 0 comments 0 0 Recent Activity: Mar 24 Dinakaran Pannerselvam Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha) , B.1.351 (beta),and B.1.617.2 (delta) variants. However, the B.1.1.529 (omicron) variant harbors multiple mutations that can mediate immune evas Views 0 comments 0 0 Recent Activity: Feb 26 Dinakaran Pannerselvam Nervous system consequences of COVID-19 Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a respiratory pathogen, myriad neurologic complications—including confusion, stroke, and neuromuscular disorders—manifest during acute COVID-19. Furthermore, maladies such as impaired concentration, headache, sensory Views 0 comments 0 0 Recent Activity: Jan 27 Vivian Creative SARS-CoV-2 Spike-pseudovirus Based Neutralization Assay Pseudovirus’ Role in Evaluating Vaccine / Drug Neutralization Ability The ability of vaccines or drugs to neutralize viruses is an important sign of their efficacy in preventing or treating viral diseases. Under normal circumstances, the vaccine or drug can be directly incubated with live virus in Views 0 comments 0 0 Recent Activity: Jan 17 Vivian Creative Vaccine Discovery Services for SARS-CoV-2 Vaccine research and development has become very urgent with the emergence of new diseases, increased burden of infectious disease, and growing concern regarding vaccine safety. Creative Biolabs has more than a decade of experience and deep expertise in vaccine discovery and development, and we ar Views 0 comments 0 2 Recent Activity: Dec 17, 2021 Dinakaran Pannerselvam Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern The Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) is an independent group of experts that periodically monitors and evaluates the evolution of SARS-CoV-2 and assesses if specific mutations and combinations of mutations alter the behaviour of the virus. The TAG-VE was convened on 26 Views 0 comments 0 0 Recent Activity: Dec 01, 2021 Dinakaran Pannerselvam SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract The mode of acquisition and causes for the variable clinical spectrum of coronavirus disease 2019 (COVID-19) remain unknown. We utilized a reverse genetics system to generate a GFP reporter virus to explore severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis and a luciferase re Views 1 comment 1 0 Recent Activity: Aug 16, 2021 ksuniliee A Case Report Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia One of the article published in NCBI This paper reports for the first time, the outcomes of Ayurvedic intervention in a COVID-19 patient with severe hypoxia requiring supportive oxygen therapy. Patient developed fever, severe cough, loss of smell, loss of taste, nasal block, anorexia, headache, b Views 1 comment 1 0 Recent Activity: May 21, 2021 Dinakaran Pannerselvam Household COVID-19 risk and in-person schooling In-person schooling has proved contentious and difficult to study throughout the SARS-CoV-2 pandemic. Data from a massive online survey in the United States indicates an increased risk of COVID-19-related outcomes among respondents living with a child attending school in-person. School-based mitigat Views 0 comments 0 0 Recent Activity: May 01, 2021 Dinakaran Pannerselvam Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines Over the last two decades, there have been three deadly human outbreaks of Coronaviruses (CoVs) caused by emerging zoonotic CoVs: SARS-CoV, MERS-CoV, and the latest highly transmissible and deadly SARS-CoV-2, which has caused the current COVID-19 global pandemic. All three deadly CoVs originated fro Views 0 comments 0 0 Recent Activity: Apr 28, 2021 Dinakaran Pannerselvam Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection Importance Detailed information about the association of COVID-19 with outcomes in pregnant individuals compared with not-infected pregnant individuals is much needed. Objective To evaluate the risks associated with COVID-19 in pregnancy on maternal and neonatal outcomes compared with not-infected Views 0 comments 0 0 Recent Activity: Apr 27, 2021 Dinakaran Pannerselvam Association between periodontitis and severity of COVID‐19 infection: A case–control study COVID‐19 is associated with an exacerbated inflammatory response that can result in fatal outcomes. Systemic inflammation is also a main characteristic of periodontitis. Therefore, we investigated the association of periodontitis with COVID‐19 complications. A case–control study was performed using Views 0 comments 0 0 Recent Activity: Apr 24, 2021 Dinakaran Pannerselvam Anti-SARS-CoV-2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination After trials demonstrated 94-95% efficacy in preventing coronavirus disease 2019 (COVID-19), two 54 lipid nanoparticle-formulated, nucleoside-modified messenger RNA-based vaccines received emergency use authorization by the U.S. Food and Drug Administration in December 2020.1 55 Although no lactatin Views 0 comments 0 0 Recent Activity: Apr 21, 2021 ksuniliee AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets EMA confirms overall benefit-risk remains positive EMA’s safety committee ( PRAC ) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took Views 0 comments 0 0 Recent Activity: Apr 12, 2021 Forum - Frameless

View All

Forum Posts (463)

View All